MAPK

HPK1-IN-25 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an enzymatic activity IC50 of 129 nM. This compound is valuable for cancer research, as HPK1 plays a significant role in regulating cell proliferation and apoptosis. Researchers may utilize HPK1-IN-25 to investigate its effects on tumor growth and lymphocyte signaling pathways.

MAPKAPK5-IN-1 is a specific inhibitor of MAPKAPK5, a key regulator involved in inflammatory pathways. This substituted triazolopyrazine compound demonstrates potent inhibition of MAPKAPK5 activity, making it a valuable tool for studying the molecular mechanisms underlying rheumatoid arthritis and related inflammatory conditions. Its application in research could provide insights into potential therapeutic targets for these diseases.

RMM-46 is a selective inhibitor of MAPKAPK2 (MK2), functioning as a reversible covalent modulator. It demonstrates significant biological activity in inhibiting MSK/RSK-family kinases, making it a valuable tool for research focusing on cellular signaling pathways. RMM-46 is particularly useful in studies related to cancer biology and stress response mechanisms, facilitating a deeper understanding of MK2's role in various physiological and pathological conditions.

Trametiglue is a highly selective MEK inhibitor that targets both KSR-MEK and RAF-MEK pathways. It demonstrates exceptional potency through unique interfacial binding interactions, making it a valuable tool for investigating MEK-related signaling in various cancer models. Trametiglue is suitable for research applications focused on cancer biology, drug resistance mechanisms, and the development of targeted therapies.

Atebimetinib is a novel dual MEK inhibitor that targets the MEK signaling pathway, playing a critical role in cellular proliferation and survival. It demonstrates significant anti-pancreatic cancer activity, making it a valuable reagent for cancer research. This compound is suitable for studies focused on understanding MEK-related signaling mechanisms and developing targeted therapies for pancreatic and other cancers.

Luvometinib is a selective MEK inhibitor that demonstrates antitumor activity by inhibiting the MAPK/ERK signaling pathway. It is employed in research focused on cancer biology, particularly in the study of various malignancies characterized by aberrant MEK signaling. Luvometinib is valuable for investigating therapeutic strategies aimed at enhancing targeted cancer treatments.

MEK4 inhibitor-1 is a selective MEK4 inhibitor that demonstrates potent activity against pancreatic adenocarcinoma with an IC50 value of 61 nM. This compound is utilized in research to investigate the role of MEK4 signaling in cancer progression and therapeutic resistance. Its application in preclinical studies can provide insights into potential treatment strategies targeting MEK4 in various malignancies.

Envometinib is a dual MEK inhibitor that utilizes Deep Cyclic Inhibition (DCI) as its primary mechanism of action. It demonstrates significant antitumor activity across various in vivo models, making it a valuable tool for cancer research. Envometinib is particularly relevant for studies involving RAS and RAF mutated cancers, such as colorectal cancer and melanoma.

MEK-IN-7 is a potent, orally available, and selective inhibitor of MEK1, demonstrating an IC50 of 29.62 nM. This compound effectively inhibits the proliferation of HT29 and A375 cancer cell lines, with IC50 values of 0.62 nM and 0.40 nM, respectively. Additionally, MEK-IN-7 has been shown to suppress tumor growth in HL-29 xenograft mouse models, making it a valuable reagent for research in melanoma and colon cancer.

GW284543 hydrochloride is a selective inhibitor of MEK5, a key regulator in the MAPK signaling pathway. This compound effectively reduces phosphorylated ERK5 (pERK5) levels while decreasing the endogenous MYC protein. It is valuable for research applications investigating cellular signaling pathways, tumor biology, and potential therapeutic targets in various cancers.

MEK-IN-8 is a potent MEK inhibitor with an IC50 of less than 5 nM for phosphorylated MEK in A549 cells. This compound is valuable for investigating the MEK/ERK signaling pathway and its role in tumorigenesis. MEK-IN-8 is a useful tool for preclinical studies aimed at understanding cancer biology and potential therapeutic interventions.

MEK4 inhibitor-2 is a selective inhibitor targeting the MEK4 pathway, exhibiting an IC50 of 83 nM. It demonstrates significant biological activity against pancreatic adenocarcinoma, making it a valuable reagent for cancer research. This compound can be utilized in studies exploring the role of MEK4 in tumor progression and therapeutic responses.

Pimasertib hydrochloride is a selective allosteric inhibitor of MEK1/2, functioning through non-competitive inhibition of ATP-binding. This compound is notable for its ability to effectively block the MAPK signaling pathway, which is crucial in various cancers. Pimasertib is utilized in research focused on cancer therapeutics and cell signaling mechanisms, making it a valuable tool for studying tumor progression and drug resistance.

BAY-866 is an allosteric inhibitor of MEK1, exhibiting an IC50 of 14 nM. This compound effectively inhibits cell proliferation in A375 (BRAF) and HCT116 (K-Ras) cell lines, with respective IC50 values of 13 nM and 277 nM. Additionally, BAY-866 demonstrates anti-tumor activity in K-Ras-mutated A549 xenograft models, making it a valuable tool for research in cancer biology and targeted therapies.

(R)-PD 0325901CL is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), a key regulator in the MAPK signaling pathway. This compound demonstrates significant antitumor activity, effectively inhibiting the proliferation of cancer cells both in vitro and in vivo. Its utility in cancer research makes it a valuable reagent for studies focused on targeted therapies and the elucidation of MEK-related mechanisms in oncogenesis.

MEK-IN-4 is a potent MEK inhibitor that specifically targets the MEK signaling pathway. It demonstrates significant biological activity in modulating cellular responses associated with inflammatory disorders and various types of cancer. This compound is an invaluable tool for research applications focused on understanding MEK-related signaling mechanisms in disease processes and therapeutic interventions.

Polfurmetinib hydrate is a potent MEK inhibitor, exhibiting an IC50 of 2 nM against A375 melanoma cells. This compound effectively hinders the MEK signaling pathway, making it a valuable tool for studies of cancer biology and therapeutic development. Its selective inhibition of MEK allows for insights into cellular signaling mechanisms and contributes to research on targeted cancer therapies.

MEK-IN-1 is a selective inhibitor of MEK (Mitogen-Activated Protein Kinase Kinase), targeting the MAPK signaling pathway. It demonstrates significant anti-proliferative effects on various cancer cell lines by blocking MEK-mediated phosphorylation of downstream ERK proteins. This compound is valuable for research applications focused on cancer biology, specifically in understanding MEK/ERK signaling and exploring therapeutic strategies for MEK-related malignancies.

UC-773587 is a selective inhibitor of SOS1 catalytic activity. By specifically binding to the catalytic site of SOS1, it inhibits nucleotide exchange with an IC50 of 4.5 μM, while demonstrating minimal interaction with HRas and ITSN. This compound is valuable for research into signaling pathways and has potential applications in the study of prostate cancer.

SOS1-IN-21 is a potent inhibitor of son of Sevenless 1 (SOS1) with an IC50 of 15 nM. As a guanine nucleotide exchange factor (GEF), SOS1 plays a critical role in the activation of KRAS by promoting GDP-GTP exchange. SOS1-IN-21 demonstrates significant antiproliferative effects, exhibiting IC50 values of 16 nM in NCI-H358 and 17 nM in Mia Paca-2 cell lines. Additionally, it shows substantial antitumor activity in the Mia Paca-2 xenograft model, making it a valuable tool for research on KRAS mutant tumors, including pancreatic cancer.